{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,11]],"date-time":"2026-10-11T03:19:57Z","timestamp":1791688797295,"version":"4.3.4"},"reference-count":28,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,12,30]],"date-time":"2024-12-30T00:00:00Z","timestamp":1735516800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000890","name":"National Multiple Sclerosis Society","doi-asserted-by":"publisher","award":["SI-2103\\u201337,386"],"award-info":[{"award-number":["SI-2103\\u201337,386"]}],"id":[{"id":"10.13039\/100000890","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","msard-journal.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1016\/j.msard.2024.106253","type":"journal-article","created":{"date-parts":[[2024,12,29]],"date-time":"2024-12-29T06:47:29Z","timestamp":1735454849000},"page":"106253","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Self-reported longitudinal COVID-19 vaccination reactogenicity profiles in persons with multiple sclerosis"],"prefix":"10.1016","volume":"94","author":[{"given":"Farren B.S.","family":"Briggs","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hollie","family":"Schmidt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Farrah J.","family":"Mateen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie","family":"Buxhoeveden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruce F.","family":"Bebo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie","family":"Fiol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael K.","family":"Racke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keisha M.","family":"Currie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heather M.","family":"Siefers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Slavka","family":"Crouthamel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura G.","family":"Kolaczkowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Phyllis","family":"Klein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert N.","family":"McBurney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Loud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.msard.2024.106253_bib0001","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2022.101542","article-title":"Immune response and reactogenicity after immunization with two-doses of an experimental COVID-19 vaccine (CVnCOV) followed by a third-fourth shot with a standard mRNA vaccine (BNT162b2): RescueVacs multicenter cohort study","volume":"51","author":"Ascaso-Del-Rio","year":"2022","journal-title":"EClinicalMedicine"},{"issue":"5","key":"10.1016\/j.msard.2024.106253_bib0002","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1056\/NEJMoa2035389","article-title":"Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine","volume":"384","author":"Baden","year":"2021","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.msard.2024.106253_bib0003","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000001104","article-title":"COVID-19 vaccination reactogenicity in persons with multiple sclerosis","volume":"9","author":"Briggs","year":"2022","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"10.1016\/j.msard.2024.106253_bib0004","unstructured":"CDC Recommends additional boosters for certain individuals [press release]. March 29, 2022 2022."},{"issue":"21","key":"10.1016\/j.msard.2024.106253_bib0005","doi-asserted-by":"crossref","first-page":"2201","DOI":"10.1001\/jama.2021.5374","article-title":"Reactogenicity following receipt of mRNA-based COVID-19 vaccines","volume":"325","author":"Chapin-Bardales","year":"2021","journal-title":"JAMa"},{"issue":"6","key":"10.1016\/j.msard.2024.106253_bib0006","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1038\/s41591-021-01325-6","article-title":"Antibody responses to the BNT162b2 mRNA vaccine in individuals previously infected with SARS-CoV-2","volume":"27","author":"Ebinger","year":"2021","journal-title":"Nat. Med."},{"key":"10.1016\/j.msard.2024.106253_bib0007","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2021.102788","article-title":"Willingness to obtain COVID-19 vaccination in adults with multiple sclerosis in the United States","volume":"49","author":"Ehde","year":"2021","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"2021","key":"10.1016\/j.msard.2024.106253_bib0008","article-title":"COVID-19 vaccine hesitancy in adults with multiple sclerosis in the United States: A follow up survey during the initial vaccine rollout in 2021","volume":"54","author":"Ehde","year":"2021","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"9","key":"10.1016\/j.msard.2024.106253_bib0009","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1136\/jnnp-2022-329123","article-title":"Multiple sclerosis disease-modifying therapies and COVID-19 vaccines: a practical review and meta-analysis","volume":"93","author":"Etemadifar","year":"2022","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.msard.2024.106253_bib0010","unstructured":"FDA Authorizes booster dose of Pfizer-BioNTech COVID-19 vaccine for certain populations [press release]. September 22, 2021 2021."},{"issue":"8","key":"10.1016\/j.msard.2024.106253_bib0011","doi-asserted-by":"crossref","first-page":"283","DOI":"10.15585\/mmwr.mm7008e3","article-title":"First month of COVID-19 vaccine safety monitoring - United States, December 14, 2020-January 13, 2021","volume":"70","author":"Gee","year":"2021","journal-title":"MMWR. Morb. Mortal. Wkly. Rep."},{"issue":"44","key":"10.1016\/j.msard.2024.106253_bib0012","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.15585\/mmwr.mm7144a3","article-title":"Safety monitoring of bivalent COVID-19 mRNA vaccine booster doses among persons aged >\/=12 Years - United States, August 31-October 23, 2022","volume":"71","author":"Hause","year":"2022","journal-title":"MMWR. Morb. Mortal. Wkly. Rep."},{"issue":"1","key":"10.1016\/j.msard.2024.106253_bib0014","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.ncl.2023.06.006","article-title":"Era of COVID-19 in multiple sclerosis care","volume":"42","author":"Krett","year":"2024","journal-title":"Neurol. Clin."},{"issue":"7","key":"10.1016\/j.msard.2024.106253_bib0015","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1016\/S1473-3099(22)00146-3","article-title":"COVID-19 vaccine waning and effectiveness and side-effects of boosters: a prospective community study from the ZOE COVID Study","volume":"22","author":"Menni","year":"2022","journal-title":"Lancet Infect. Dis."},{"issue":"10318","key":"10.1016\/j.msard.2024.106253_bib0016","doi-asserted-by":"crossref","first-page":"2258","DOI":"10.1016\/S0140-6736(21)02717-3","article-title":"Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial","volume":"398","author":"Munro","year":"2021","journal-title":"Lancet"},{"issue":"8","key":"10.1016\/j.msard.2024.106253_bib0017","doi-asserted-by":"crossref","DOI":"10.3390\/vaccines10081325","article-title":"Short-term adverse effects immediately after the start of COVID-19 booster vaccination in Vietnam","volume":"10","author":"Nguyen","year":"2022","journal-title":"Vaccines"},{"issue":"8","key":"10.1016\/j.msard.2024.106253_bib0018","doi-asserted-by":"crossref","DOI":"10.3390\/vaccines10081217","article-title":"Reactogenicity to the mRNA-1273 booster according to previous mRNA COVID-19 vaccination","volume":"10","author":"Pares-Badell","year":"2022","journal-title":"Vaccines"},{"issue":"27","key":"10.1016\/j.msard.2024.106253_bib0019","doi-asserted-by":"crossref","first-page":"2603","DOI":"10.1056\/NEJMoa2034577","article-title":"Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine","volume":"383","author":"Polack","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.msard.2024.106253_bib0013","unstructured":"iConquerMS. The COVER-MS study (COVID-19 vaccine response in MS) 2021 [Available from: https:\/\/www.iconquerms.org\/cover-ms-description."},{"key":"10.1016\/j.msard.2024.106253_bib0020","unstructured":"Prevention CfDCa. Interim clinical considerations for use of COVID-19 vaccines in the United States 2024 [Available from: https:\/\/www.cdc.gov\/vaccines\/covid-19\/clinical-considerations\/interim-considerations-us.html."},{"key":"10.1016\/j.msard.2024.106253_bib0021","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.15585\/mmwr.mm7242e1","article-title":"Use of Updated COVID-19 Vaccines 2023\u20132024 formula for persons aged \u22656 months: recommendations of the advisory committee on immunization practices \u2014 United States, September 2023","volume":"72","author":"Regan","year":"2023","journal-title":"MMWR. Morb. Mortal. Wkly. Rep."},{"issue":"23","key":"10.1016\/j.msard.2024.106253_bib0022","doi-asserted-by":"crossref","first-page":"2187","DOI":"10.1056\/NEJMoa2101544","article-title":"Safety and efficacy of single-dose Ad26.COV2.S vaccine against Covid-19","volume":"384","author":"Sadoff","year":"2021","journal-title":"N. Engl. J. Med."},{"issue":"18","key":"10.1016\/j.msard.2024.106253_bib0023","doi-asserted-by":"crossref","first-page":"680","DOI":"10.15585\/mmwr.mm7018e2","article-title":"Safety monitoring of the Janssen (Johnson & Johnson) COVID-19 vaccine - United States, March-April 2021","volume":"70","author":"Shay","year":"2021","journal-title":"MMWR. Morb. Mortal. Wkly. Rep."},{"key":"10.1016\/j.msard.2024.106253_bib0024","unstructured":"Society NMS. Multiple sclerosis and COVID-19 2024 [Available from: https:\/\/www.nationalmssociety.org\/managing-ms\/living-with-ms\/diet-exercise-and-healthy-behaviors\/vaccination\/covid."},{"issue":"10","key":"10.1016\/j.msard.2024.106253_bib0025","doi-asserted-by":"crossref","DOI":"10.3390\/vaccines11101513","article-title":"Multivariate analysis of adverse reactions and recipient profiles in COVID-19 booster vaccinations: a prospective cohort study","volume":"11","author":"Urakawa","year":"2023","journal-title":"Vaccines"},{"issue":"10269","key":"10.1016\/j.msard.2024.106253_bib0026","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/S0140-6736(20)32661-1","article-title":"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK","volume":"397","author":"Voysey","year":"2021","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.msard.2024.106253_bib0027","article-title":"COVID-19 vaccination willingness among people with multiple sclerosis","volume":"7","author":"Xiang","year":"2021","journal-title":"Mult. Scler. J. Exp. Transl. Clin."},{"issue":"13","key":"10.1016\/j.msard.2024.106253_bib0028","doi-asserted-by":"crossref","first-page":"1924","DOI":"10.1016\/j.vaccine.2022.02.052","article-title":"Association between reactogenicity and SARS-CoV-2 antibodies after the second dose of the BNT162b2 COVID-19 vaccine","volume":"40","author":"Yamamoto","year":"2022","journal-title":"Vaccine"}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034824008290?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034824008290?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,2,27]],"date-time":"2025-02-27T14:16:02Z","timestamp":1740665762000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211034824008290"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2]]},"references-count":28,"alternative-id":["S2211034824008290"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2024.106253","relation":{},"ISSN":["2211-0348"],"issn-type":[{"value":"2211-0348","type":"print"}],"subject":[],"published":{"date-parts":[[2025,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Self-reported longitudinal COVID-19 vaccination reactogenicity profiles in persons with multiple sclerosis","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2024.106253","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"106253"}}